Drug Profile
Research programme: metabolic disorders therapeutics - Esperion
Alternative Names: ESP 41091Latest Information Update: 28 Apr 2018
Price :
$50
*
At a glance
- Originator Esperion Therapeutics
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Metabolic disorders
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for preclinical development in Metabolic-disorders in USA (PO)
- 13 Mar 2014 Preclinical trials in Metabolic disorders in USA (PO)